title: The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
abstract: The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Jingyu
authors.initials: J
authors.lastname: Zhu
authors.forename: Biyin
authors.initials: B
authors.lastname: Cao
authors.affiliation: Laboratory of Targeted Antileukemia Drug Discovery, Cyrus Tang Hematology Center, Soochow University, 199 Ren Ai Road, Room703-507, Suzhou Industrial Park, Suzhou, China 215123. xinliangmao@suda.edu.cn.
authors.forename: Xinliang
authors.initials: X
authors.lastname: Mao
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism
chemical_list: D007166:Immunosuppressive Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases